Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
New York, NY
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Rochester, NY
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Columbus, OH
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Franklin, OH
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Franklin, OH
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Lyndhurst, OH
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Lyndhurst, OH
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Marion, OH
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Marion, OH
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Willoughby Hills, OH
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Willoughby Hills, OH
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Mount Pleasant, SC
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Summerville, SC
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Summerville, SC
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Houston, TX
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Houston, TX
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Orem, UT
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Orem, UT
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Richmond, VA
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Olympia, WA
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Olympia, WA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated:  3/21/2016
Clinical Research Facility
mi
from
Kansas City, KA
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Status: Enrolling
Updated: 3/21/2016
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Genetically Guided Statin Therapy
Genetically Guided Statin Therapy to Improve Medication Adherence
Status: Enrolling
Updated:  4/11/2016
David Grant US Air Force Medical Center
mi
from
Travis Air Force Base, CA
Genetically Guided Statin Therapy
Genetically Guided Statin Therapy to Improve Medication Adherence
Status: Enrolling
Updated: 4/11/2016
David Grant US Air Force Medical Center
mi
from
Travis Air Force Base, CA
Click here to add this to my saved trials
Genetically Guided Statin Therapy
Genetically Guided Statin Therapy to Improve Medication Adherence
Status: Enrolling
Updated:  4/11/2016
Duke University
mi
from
Durham, NC
Genetically Guided Statin Therapy
Genetically Guided Statin Therapy to Improve Medication Adherence
Status: Enrolling
Updated: 4/11/2016
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
A First-in-human Randomized, Double-blind, Placebo-controlled, 4-part Study to Assess Safety, Tolerability, Pharmacokinetics (Including Open Label Study of Food Effect and Interaction With Simvastatin) and Pharmacodynamics of Interwoven Single- and Multiple-ascending Doses of TAP311 in Healthy Subjects and Dyslipidemic Patients.
Status: Enrolling
Updated:  4/15/2016
Novartis Investigative Site
mi
from
Miramar, FL
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
A First-in-human Randomized, Double-blind, Placebo-controlled, 4-part Study to Assess Safety, Tolerability, Pharmacokinetics (Including Open Label Study of Food Effect and Interaction With Simvastatin) and Pharmacodynamics of Interwoven Single- and Multiple-ascending Doses of TAP311 in Healthy Subjects and Dyslipidemic Patients.
Status: Enrolling
Updated: 4/15/2016
Novartis Investigative Site
mi
from
Miramar, FL
Click here to add this to my saved trials
Physiological Study of Human Cholesterol Metabolism and Excretion
Reverse Cholesterol Transport in Humans
Status: Enrolling
Updated:  5/5/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Physiological Study of Human Cholesterol Metabolism and Excretion
Reverse Cholesterol Transport in Humans
Status: Enrolling
Updated: 5/5/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles
A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles
Status: Enrolling
Updated:  5/10/2016
USDA Beltsville Human Nutrition Research Center
mi
from
Beltsville, MD
A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles
A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles
Status: Enrolling
Updated: 5/10/2016
USDA Beltsville Human Nutrition Research Center
mi
from
Beltsville, MD
Click here to add this to my saved trials
Ranolazine for the Treatment of Chest Pain in HCM Patients
Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation
Status: Enrolling
Updated:  5/11/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Ranolazine for the Treatment of Chest Pain in HCM Patients
Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation
Status: Enrolling
Updated: 5/11/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Park Nicollet- Brookdale
mi
from
Brooklyn Center, MN
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Park Nicollet- Brookdale
mi
from
Brooklyn Center, MN
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Ridgeview Medical Center
mi
from
Delano, MN
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Ridgeview Medical Center
mi
from
Delano, MN
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Essentia Health-Lakeside Clinic
mi
from
Duluth, MN
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Essentia Health-Lakeside Clinic
mi
from
Duluth, MN
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Fairview Clinic-Eagan
mi
from
Eagan, MN
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Fairview Clinic-Eagan
mi
from
Eagan, MN
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Park Nicollet-Golden Valley
mi
from
Golden Valley, MN
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Park Nicollet-Golden Valley
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Essentia Hermantown Clinic
mi
from
Hermantown, MN
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Essentia Hermantown Clinic
mi
from
Hermantown, MN
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Native American Community Clinic
mi
from
Minneapolis, MN
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Native American Community Clinic
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Community Health Service, Inc.
mi
from
Rochester, MN
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Community Health Service, Inc.
mi
from
Rochester, MN
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
The Mayo Clinic
mi
from
Rochester, MN
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Fairview Medical-Rosemount
mi
from
Rosemount, MN
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Fairview Medical-Rosemount
mi
from
Rosemount, MN
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Baldwin Area Medical Center, Inc.
mi
from
Baldwin, WI
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Baldwin Area Medical Center, Inc.
mi
from
Baldwin, WI
Click here to add this to my saved trials
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated:  5/23/2016
Hudson Physicians S.C.
mi
from
Hudson, WI
Use of Decision Aids in Clinical Encounters
Patient-centered Dissemination of Evidence-based Medicine: Share EBM
Status: Enrolling
Updated: 5/23/2016
Hudson Physicians S.C.
mi
from
Hudson, WI
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
IMD Medical Group
mi
from
Los Angeles, CA
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
IMD Medical Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
The Hartford Hospital
mi
from
Hartford, CT
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
Best Quality Research Inc.
mi
from
Hialeah, FL
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
Best Quality Research Inc.
mi
from
Hialeah, FL
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
NewPhase Clinical Trials, Corp.
mi
from
Miami Beach, FL
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
NewPhase Clinical Trials, Corp.
mi
from
Miami Beach, FL
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
Medical Research Center
mi
from
Miami, FL
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
Medical Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
OM Medical
mi
from
Las Vegas, NV
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
OM Medical
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
The University of North Carolina at Chapel Hill - Center for Heart & Vascular Care
mi
from
Chapel Hill, NC
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
The University of North Carolina at Chapel Hill - Center for Heart & Vascular Care
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
The University of North Carolina Hospitals- Clinical and Translational Research Center Clinic
mi
from
Chapel Hill, NC
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
The University of North Carolina Hospitals- Clinical and Translational Research Center Clinic
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
Oklahoma Heart Hospital Physicians
mi
from
Oklahoma City, OK
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
Oklahoma Heart Hospital Physicians
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
Oklahoma Heart Hospital Research Foundation
mi
from
Oklahoma City, OK
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
Oklahoma Heart Hospital Research Foundation
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
OnSite Clinical Solutions, LLC
mi
from
Gaffney, SC
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
OnSite Clinical Solutions, LLC
mi
from
Gaffney, SC
Click here to add this to my saved trials
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  6/13/2016
Galenos Research
mi
from
Dallas, TX
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 6/13/2016
Galenos Research
mi
from
Dallas, TX
Click here to add this to my saved trials